3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
5
Multiple Myeloma
2
Lymphoma
2
Hematologic Neoplasms
2
Colorectal Neoplasms
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Solid Tumors
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Pathologic Complete Response
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Neoplasm, Residual
1
Neoplasm Metastasis
1
Melanoma
1
Lung Neoplasms
1
Hemangiosarcoma
1
HER2-positive Metastatic Breast Cancer
1
HER2-Positive Primary Breast Cancer
1
Glioma
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Renal Cell
1
Interventions
Cyclophosphamide
11
fludarabine phosphate
8
Nivolumab
8
pembrolizumab
7
fludarabine
7
Mycophenolic Acid
6
Magnetic Resonance Spectroscopy
6
Filgrastim
6
Doxorubicin
6
Dacarbazine
6
Brentuximab Vedotin
6
Whole-Body Irradiation
5
Vinblastine
5
Granulocyte Colony-Stimulating Factor
5
Cyclosporine
5
Specimen Handling
4
Melphalan
4
Etoposide
4
Busulfan
4
pegfilgrastim
3
Tacrolimus
3
Radiotherapy
3
Thiotepa
2
Sirolimus
2
Radiation
2
Peripheral Blood Stem Cell Transplantation
2
Fluorodeoxyglucose F18
2
Cyclosporins
2
Clofarabine
2
Azacitidine
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Hodgkin Disease
×
Ado-Trastuzumab Emtansine
×
30 days
×
Clear all
No trials found.